S
Silvia Damaso
Researcher at GlaxoSmithKline
Publications - 21
Citations - 3312
Silvia Damaso is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Vaccination & Rotavirus. The author has an hindex of 11, co-authored 19 publications receiving 3164 citations.
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis
Guillermo M. Ruiz-Palacios,Irene Pérez-Schael,F. Raúl Velázquez,Hector Abate,Thomas Breuer,Sue Ann Costa Clemens,Brigitte Cheuvart,Felix Espinoza,Paul Gillard,Bruce L. Innis,Yolanda Cervantes,Alexandre da Costa Linhares,Pio Lopez,Mercedes Macias-Parra,Eduardo Ortega-Barria,Vesta Richardson,Doris Maribel Rivera-Medina,Luis Rivera,Belén Salinas,Noris Pavía-Ruz,Jorge Salmerón,Ricardo Rüttimann,Juan Carlos Tinoco,Pilar Rubio,Ernesto Nuñez,M. Lourdes Guerrero,Juan Pablo Yarzabal,Silvia Damaso,Nadia Tornieporth,Xavier Sáez-Llorens,Rodrigo Vergara,Timo Vesikari,Alain Bouckenooghe,Ralf Clemens,Beatrice De Vos,Miguel O'Ryan +35 more
TL;DR: Two oral doses of the live attenuated G1P[8] HRV vaccine were highly efficacious in protecting infants against severe rotavirus gastroenteritis, significantly reduced the rate of severe gastroenteropathy from any cause, and were not associated with an increased risk of intussusception.
Journal ArticleDOI
Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study
Timo Vesikari,Aino Karvonen,Roman Prymula,Volker Schuster,J. C. Tejedor,Robert Cohen,F Meurice,H.H. Han,Silvia Damaso,Alain Bouckenooghe +9 more
TL;DR: In a European setting, two doses of RIX4414 coadministered with childhood vaccines provided high protection against any and severe rotavirus gastroenteritis, with an overall reduction of admissions for gastroEnteritis over two consecutive rotav virus epidemic seasons.
Journal ArticleDOI
Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study.
Alexandre da Costa Linhares,F. Raúl Velázquez,Irene Pérez-Schael,Xavier Sáez-Llorens,Hector Abate,Felix Espinoza,Pio Lopez,Mercedes Macias-Parra,Eduardo Ortega-Barria,Doris Maribel Rivera-Medina,Luis Rivera,Noris Pavía-Ruz,Ernesto Nuñez,Silvia Damaso,Guillermo M. Ruiz-Palacios,Beatrice De Vos,Miguel O'Ryan,Paul Gillard,Alain Bouckenooghe +18 more
TL;DR: Two doses of RIX4414 were effective against severe rotavirus gastroenteritis during the first 2 years of life in a Latin American setting and inclusion of Rix4414 in routine paediatric immunisations should reduce the burden of rotav virus gastroEnteritis worldwide.
Journal ArticleDOI
Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.
Belén Salinas,Irene Pérez Schael,Alexandre da Costa Linhares,Guillermo M Ruiz Palacios,M. Lourdes Guerrero,Juan Pablo Yarzabal,Yolanda Cervantes,SueAnn Costa Clemens,Silvia Damaso,Karin Hardt,Beatrice De Vos +10 more
TL;DR: Two doses of RIX4414 are highly efficacious, providing cross-protection against any and severe rotavirus gastroenteritis and hospitalization to infants in Latin America and proof of concept that the monovalent G1P1A P[8] human rotav virus vaccine elicits cross- protection against the G9 strain.
Journal ArticleDOI
Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study
TL;DR: These data do not show a protective effect of either 1 or 2 vaccine doses against S. aureus bacteremia in ESRD patients, and suggested possible suboptimal vaccine quality (manufacturing) and a need to expand the antigen composition of the vaccine.